Dong-E-E-Jiao's 2025 Performance Shows Steady Growth, Strategic Deepening and Governance Optimization Advancing in Tandem

Data from Zhongfang.com: Dong-E E-Jiao Co., Ltd. (hereinafter referred to as “Dong-E E-Jiao”) recently released its 2025 Board of Directors Work Report, systematically reviewing the company’s key progress in strategy implementation, governance optimization, operational performance, and future planning. The report shows that in 2025, the company achieved operating revenue of 6.7 billion yuan, a year-on-year increase of 13.17%; net profit attributable to shareholders of the listed company was 1.739 billion yuan, up 11.67%, with overall improvement in operating quality.

At the strategic level, the board of directors anchored the annual theme of “Growth · Breakthrough,” fully implementing the “1238” development strategy, which aims to firmly establish the positioning as “the most trusted health supplement leader for the masses,” deepen the dual-driven approach of pharmaceuticals and health consumer products, culture, and industry, promote integration of primary, secondary, and tertiary industries, and systematically enhance eight core capabilities. The board held 12 meetings throughout the year, reviewing 54 proposals, efficiently fulfilling its responsibilities of “setting strategy, making decisions, and preventing risks.”

Corporate governance continued to improve. In 2025, Dong-E E-Jiao legally completed the reform to abolish the supervisory committee, with its functions transferred to the Audit Committee of the board, and added employee representatives as directors. The board established specialized committees to standardize operations, holding 26 meetings throughout the year to provide professional support for scientific decision-making. The company continued to promote the first phase of its restricted stock incentive plan, completing the initial grant registration in July, aiming to improve the long-term incentive and restraint mechanism.

Innovation in R&D and market value management became highlights. The company strengthened its “One Center, Three High Grounds + N Joint” R&D layout and successfully obtained approval for the National Enterprise Technology Center. Meanwhile, the company established a value co-sharing core system for market value management, striving to become the best practice leader in market value management among traditional Chinese medicine listed companies. Regarding investor returns, the mid-year dividend plan for 2025 proposes a cash dividend of 12.69 yuan per 10 shares, maintaining industry-leading dividend payout levels.

Looking ahead to 2026, the board will focus on the theme of “Growth · Innovation,” promote the start of the “14th Five-Year Plan,” continue to deepen the dual-driven approach and industry integration, strengthen R&D investment to cultivate new productive forces, and improve comprehensive risk management systems to ensure high-quality development of the company.